ReviewInternational journal of antimicrobial agents2014
Treatment and prophylaxis of melioidosis.
Review in International journal of antimicrobial agents, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
169 citing papers in PubMed, 2 syntheses or guidelines pooled it, 315 citations in OpenAlex.
- Neonatal patients with melioidosis: a systematic review.BMC infectious diseases · 2025Pooled it
- Efficacy and safety of co-trimoxazole in eradication phase of melioidosis; systematic review.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- Timing of surgery for a melioidosis-associated abdominal aortic pseudoaneurysm: a case report.Tropical medicine and health · 2026Article
- Outcomes of patients with suspected or confirmed melioidosis: A prospective multinational, multicenter, observational study.PLoS neglected tropical diseases · 2026Observational
- Treatment of melioidosis in cats and dogs: antimicrobial therapy and clinical guidance for Burkholderia pseudomallei infections.Australian veterinary journal · 2026Article
- Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim-Sulfamethoxazole Resistance in Burkholderia thailandensis.ACS infectious diseases · 2026Article
- Article
- Drug screening to identify compounds to eliminateiScience · 2026Article
- A hidden culprit: Unusual thyroid involvement in melioidosis-A case report.Infectious diseases & immunity · 2026Article
- Development of an antigen detection test kit (Melioidosis-ATK) for point-of-care diagnosis of melioidosis.Microbiology spectrum · 2026Article
- Genetic Engineering of Lysogenic-Lytic Switch Genes ImprovesInternational journal of molecular sciences · 2026Article
- Contiguous spread of melioidosis to the brain: a rare case of subdural empyema following odontogenic infection. Illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Article
- Article
- A 39-year-old man with high-grade fever, multiple cavitating lung nodules, and skin and liver lesions.Breathe (Sheffield, England) · 2026Article
- Factors Related to Wildlife Consumption, Contact, and Environmental Exposures Across Ethnic Communities in Border Provinces of Thailand: A Quantitative One Health Study.International journal of veterinary science and medicine · 2026Article
- The epidemiology and clinical features of melioidosis in the Lao PDR: a 21-year prospective hospital-based cohort study.BMC infectious diseases · 2025Article
- Ecological Diversity, Metabolic Versatility, and Biotechnological Applications ofAntibiotics (Basel, Switzerland) · 2025Review
- Phage-mediated control of melioidosis in Southern China: molecular insights and therapeutic potential of N4-like viruses from Hainan.BMC microbiology · 2025Article
- Pharmacokinetics and in vivo efficacy of epetraborole against Burkholderia pseudomallei.Scientific reports · 2025Article
109 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
Melioidosis, infection with Burkholderia pseudomallei, is being recognised with increasing frequency and is probably more common than currently appreciated. Treatment recommendations are based on a series of clinical trials conducted in Thailand over the past 25 years. Treatment is usually divided into two phases: in the first, or acute phase, parenteral drugs are given for ≥10 days with the aim of preventing death from overwhelming sepsis; in the second, or eradication phase, oral drugs are given, usually to complete a total of 20 weeks, with the aim of preventing relapse. Specific treatment for individual patients needs to be tailored according to clinical manifestations and response, and there remain many unanswered questions. Some patients with very mild infections can probably be cured by oral agents alone. Ceftazidime is the mainstay of acute-phase treatment, with carbapenems reserved for severe infections or treatment failures and amoxicillin/clavulanic acid (co-amoxiclav) as second-line therapy. Trimethoprim/sulfamethoxazole (co-trimoxazole) is preferred for the eradication phase, with the alternative of co-amoxiclav. In addition, the best available supportive care is needed, along with drainage of abscesses whenever possible. Treatment for melioidosis is unaffordable for many in endemic areas of the developing world, but the relative costs have reduced over the past decade. Unfortunately there is no likelihood of any new or cheaper options becoming available in the immediate future. Recommendations for prophylaxis following exposure to B. pseudomallei have been made, but the evidence suggests that they would probably only delay rather than prevent the development of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.